Admission characteristics and laboratory parameters of trial patients and historical controls*
| . | Trial patients . | Historical control patients . | P . |
|---|---|---|---|
| Female:male | 26:14 | 33:7 | 1.0 |
| De novo: relapsed | 34:6 | 31:9 | 1.0 |
| Ethnicity | 22 White (12 F, 10 M) | 26 White (22 F, 4 M) | |
| 13 A/C (10 F, 3 M) | 11 A/C (9 F, 2 M) | ||
| 5 Other (4 F, 1 M) | 3 Other: (2 F, 1 M) | ||
| Median age (range) | 42 (21-76) | 42 years (18-78 years) | .4 |
| Symptoms | Neurologic: 31 of 40 | Neurologic: 29 of 40 | .09 (including cardiac cases) |
| Fever: 19 of 40 | Fever: 15 of 40 | .2 (excluding cardiac cases) | |
| Renal: 17 of 40 | Renal: 10 of 38 | ||
| Abdominal: 19 of 40 | Abdominal: 14 of 38 | ||
| Cardiac: 19 of 40 | Cardiac: 4 of 37† | ||
| Median Hb, g/d L (range) | 8.6 (3.7-13.8) | 8.5 (4.8-15) | .7 |
| Median platelets, ×109/L (range) | 13 (5-60) | 14 (4-84) | .7 |
| Median LDH, IU (range) | 2088 (498-4565) | 1724 (274-5042) | .7 |
| Median bilirubin, μmol/L, day 1 (range) | 51 (9-141) | 46 (8-179) | .8 |
| Median creatinine, μmol/L (range) | 94 (52-353) | 94 (61-516) | .8 |
| Median ADAMTS13 activity, % (range) | < 5% (< 5%-32%) | < 5%(< 5%-40%) | .97 |
| Median anti-ADAMTS13 IgG, % (range) | 40% (6%-162%) | 78% (8%-140%) | .25 |
| . | Trial patients . | Historical control patients . | P . |
|---|---|---|---|
| Female:male | 26:14 | 33:7 | 1.0 |
| De novo: relapsed | 34:6 | 31:9 | 1.0 |
| Ethnicity | 22 White (12 F, 10 M) | 26 White (22 F, 4 M) | |
| 13 A/C (10 F, 3 M) | 11 A/C (9 F, 2 M) | ||
| 5 Other (4 F, 1 M) | 3 Other: (2 F, 1 M) | ||
| Median age (range) | 42 (21-76) | 42 years (18-78 years) | .4 |
| Symptoms | Neurologic: 31 of 40 | Neurologic: 29 of 40 | .09 (including cardiac cases) |
| Fever: 19 of 40 | Fever: 15 of 40 | .2 (excluding cardiac cases) | |
| Renal: 17 of 40 | Renal: 10 of 38 | ||
| Abdominal: 19 of 40 | Abdominal: 14 of 38 | ||
| Cardiac: 19 of 40 | Cardiac: 4 of 37† | ||
| Median Hb, g/d L (range) | 8.6 (3.7-13.8) | 8.5 (4.8-15) | .7 |
| Median platelets, ×109/L (range) | 13 (5-60) | 14 (4-84) | .7 |
| Median LDH, IU (range) | 2088 (498-4565) | 1724 (274-5042) | .7 |
| Median bilirubin, μmol/L, day 1 (range) | 51 (9-141) | 46 (8-179) | .8 |
| Median creatinine, μmol/L (range) | 94 (52-353) | 94 (61-516) | .8 |
| Median ADAMTS13 activity, % (range) | < 5% (< 5%-32%) | < 5%(< 5%-40%) | .97 |
| Median anti-ADAMTS13 IgG, % (range) | 40% (6%-162%) | 78% (8%-140%) | .25 |
A/C indicates Afro-Caribbean.
Shown is a comparison of cases and controls with no evidence of statistical difference between all the categories highlighted other than cardiac (due to the unavailability/testing of troponin levels).
There were fewer cardiac cases because troponin T levels were not available throughout this period.